Please login to the form below

Not currently logged in
Email:
Password:

First Predictive biomarker for lung cancer

High EGFR expression is a predictor for improved survival with cetuximab and chemotherapy, according to new research

High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

Principal investigator Dr Robert Pirker, of the Medical University of Vienna in Austria, said: "By demonstrating that high EGFR expression is the first predictive biomarker for improved overall survival in advanced NSCLC [non-small cell lung cancer], we have taken a major step towards a more personalised approach in this difficult-to-treat disease."

The latest analysis of FLEX patients (1,121 out of 1,125 FLEX study patients), found that patients with high tumour EGFR expression (200 and above on a scale of 0-300) consistently benefited from the addition of cetuximab to chemotherapy regardless of histology. Within this group, overall survival averaged 12 months, compared with 9.6 months for patients receiving chemotherapy alone.

In patients with low EGFR expression, no difference in overall survival was seen between patients receiving chemotherapy with cetuximab, compared to those receiving chemotherapy alone.

5th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics